Article

‘You Never Know When Things Could Change in an Instant’ Says Pediatric Cancer Survivor

In an interview with CURE®, Emily Whitehead details her journey as a pediatric cancer survivor and how you won’t be able to predict it.

Emily Whitehead was just five years old when she was diagnosed with standard-risk pre-b acute lymphoblastic leukemia (ALL) in 2010. Though her parents, Tom and Kari, were told that she had a good chance of recovery, Emily underwent 16 months of chemotherapy. Then, just two weeks before a scheduled bone marrow transplant, Emily relapsed for a second time.

The Whiteheads thought they were out of options, until a phase 1 trial examining the use of CAR-T cell therapy opened up at Children’s Hospital of Philadelphia (CHOP) in April 2012, making Emily the first child to receive CAR-T cell therapy. This treatment turned out to be what the Whiteheads now call a miracle, and here, Emily, who has been in remission since May 2012, offers her take on what it was like to go through treatment and offers some advice to other patients who may be in a similar situation.

Transcription:

CURE: What was it like going through cancer treatment as a child?

Emily: It's definitely a really difficult thing to go through, and you really need the support of other people, whether that be friends or family, or even a pet like my dog, Lucy. But I'm just so glad that more people have access to the treatment now, to less toxic treatments. And really all that you can do is just never stop and always keep fighting and just try to keep hoping you'll get through it.

What advice do you have for other patients with pediatric cancer?

I always tell them to never give up, to always keep fighting and to always believe in yourself and just to try and smile every day because you never know when things could change in an instant.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content